EMA Authorised: Pomalidomide Krka (Pomalidomide) — Krka, d.d., Novo mesto

View source ↗

Summary

The EMA authorised Pomalidomide Krka for the treatment of multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalidomide Krka (pomalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Krka, d.d., Novo mesto. Decision date: 10/07/2025